SynthesisHaematologica2019
The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.
Synthesis in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05729464 (Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism), which is not on this map. Cited by 182 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
Who cites it
182 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.Journal of thrombosis and haemostasis : JTH · 2024Pooled it
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.The Cochrane database of systematic reviews · 2020Pooled it
- The effectiveness and safety of thromboprophylaxis in cancer patients based on Khorana score: a meta-analysis and systematic review of randomized controlled trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Pooled it
- Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.Blood advances · 2020Pooled it
- Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors.Blood advances · 2020Pooled it
- Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients.Haematologica · 2020Pooled it
- Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Growth differentiation factor-15 for prediction of bleeding in cancer patients.Journal of thrombosis and haemostasis : JTH · 2022Trial
- D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.The oncologist · 2020Trial
- External validation of established clinical risk scores for cancer-associated venous thromboembolism in a Brazilian registry.Journal of thrombosis and thrombolysis · 2026Article
- The COMPASS-CAT risk assessment model for predicting in-hospital venous thromboembolism in patients with breast, lung, colorectal, and ovarian cancer: A retrospective cohort study.The Journal of international medical research · 2026Article
- Development of novel plasma proteomic biomarkers for cancer-associated thrombosis in an advanced cancer cohort.Journal of thrombosis and haemostasis : JTH · 2026Article
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.Research and practice in thrombosis and haemostasis · 2026Article
- Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.Circulation. Genomic and precision medicine · 2026Article
- A deep learning model to dynamically predict cancer-associated thromboembolism in large-scale healthcare systems.NPJ digital medicine · 2026Article
- Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management.Cancers · 2026Review
- Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.Cardio-oncology (London, England) · 2026Review
- Systemic immune-inflammation index as a predictor of venous thromboembolism in NSCLC patients treated with ICIs: a retrospective study.BMC pulmonary medicine · 2026Article
- Continuous administration of heparin during free flap surgery for head and neck tumors reduces the risk of pulmonary embolism.Oral and maxillofacial surgery · 2026Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were searched from January 2008 to June 2018 for studies which evaluated the Khorana score. Two authors independently screened studies for eligibility, extracted data, and assessed risk of bias. Additional data on the 6-month incidence of venous thromboembolism were sought by contacting corresponding authors. The incidence in each Khorana score risk group was estimated with random effects meta-analysis. A total of 45 articles and eight abstracts were included, comprising 55 cohorts enrolling 34,555 ambulatory cancer patients. For 27,849 patients (81%), 6-month follow-up data were obtained. Overall, 19% of patients had a Khorana score of 0 points, 64% a score of 1 or 2 points, and 17% a score of 3 or more points. The incidence of venous thromboembolism in the first six months was 5.0% (95%CI: 3.9-6.5) in patients with a low-risk Khorana score (0 points), 6.6% (95%CI: 5.6-7.7) in those with an intermediate-risk Khorana score (1 or 2 points), and 11.0% (95%CI: 8.8-13.8) in those with a high-risk Khorana score (3 points or higher). Of the patients with venous thromboembolism in the first six months, 23.4% (95%CI: 18.4-29.4) had been classified as high risk according to the Khorana score. In conclusion, the Khorana score can be used to select ambulatory cancer patients at high risk of venous thromboembolism for thromboprophylaxis; however, most events occur outside this high-risk group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.